when "mad money" came on the air back in 2005, our first ceo interview w interview was with regeneronirm that had been around 17 years. since then, this company has become a power house, with the stock taking off basically the surprising strength of a drug called ilea, and continuing to roar in a number of other breakthrough therapies. fast forward to 2015, and the stock traded all the way up to $592 before getting slammed by a market side selloff. for the sake of using round numbers, let's just call it $500 ten years ago, could have bought it $5. what would have happened to that $500 a gain of roughly 9,900% it's a ten bagger. but you never could have gotten in on that gigantic gain if you hadn't taken a risk in 2005 and bought a company with no profits or products on the market and only the promises of the ceo that things would work out but many similar firms have done nothing. you won't always be able to identify the winners in this space. but that's okay, as long as you cast a wide net. if you take small positions, let's say nine of them go to zero as long as the tenth one was reg

interesting, regeneron is higher, which is unexpected. no hardest day a potential blockbuster it is developing to loss.vision that would provide an advantage over regeneron. concerns aret weighing on the market area and mark carney sounded the alarm on the upcoming risks of the european union. >> i would like to see the extent to which growth is offset by other components of demand. ande wages begin to frim, generally how the economy reacts to the prospect of tighter financial conditions and the reality of brexit negotiations. nejra: he is warning the pound sliding for the second day. for more, let's bring in christine pitino. through the various factors causing this selloff in pushing the guilt yield lower. christine: he pushed back quite dovish late. risks.long-term, brexit we have been talking about this for some time. the outcome of those are unknown. do not like uncertainty or betting on unknown outcomes. that is something that will hang over investor's heads for at least two years. in terms of expectations from a rate hike from the

tech had a big selloff on friday, down 2.24% >>> sanofi and regeneron say they're anti-cholesterol drugaw positive results in the first dedicated trial involving patients with diabetes and high cholesterol. the data was presented yesterday. not much move in the share price. >>> teva stock has dropped sharply because of delays in acquisitions >>> western digital reportedly considering raising its offer for toshiba's chip unit to more than $18 billion. western digital's ceo told toshiba's president the company plans to join a consortium that includes kkr and a development bank of japan to compete with a rival off >>> amazon started hiring people to sell cars online in europe. a german straytrade magazine sah company will run the business out of luxembourg. >>> and shares of diebold could rise 25% to 40% over the next two years. the atmmaker should be able to raise margins and earnings thanks to cost synergies and the merger last year. >>> prime minister theresa may faces a showdown today as her political future hangs in the balance. all the fallout from that extraordinary vote last week a

regeneron is especially hot thanks to a positive ruling in its patent battle against amgen and the launchema drug celgene climbing 19 prts % in te second half. the worst performers, vertex falls 9%, labcorps dips 2% >> the whole sector will watch and see what becomes of that senate bill. landon, thank you. >>> now for some top trending stories. the "washington post" reporting that a fake "time" magazine cover bearing trump's image is hanging in five trump golf clubs. time has asked they be removed they read donald trump's apprentice is a splash a time spokesperson says the real time cover that week featured kate winslet. >>> cadburys has been hit by a massive cyberattack. computers at the factory stopped working last nights forring it to shut down production. it's unclear when production may resume i think there may be global capacity for chocolate production >> to make up for this never know it is broad. >> the attack is >>> britney spears' is slamming decades of lip-sync accusations. in an interview with an israeli tv show, the pop superstar admits she uses a bit of playback, but also u

regeneron up 26%, although chris raymond of raymond james thinks that the reaction has more to do with regeneron's recent successful launch of a new product, as well as the leak eed executive order on drug pricing, that doesn't call for direct price controls cooper companies and mckesson are also recent standouts, both popping up 20% but on the flip side, alexi ioi sliding 7% universal health services is lower by 3%. but if and when we do see hsa legislation, he expects hospital stocks and insurers to benefit the most >> all right, landon, thank you. kourtney, where are you yo finding value in health care >> colonel, we don't cover health care at luke capital as a sector, but our clients are absolutely buying and overweighting, whether it is buying some of the etfs to get broader exposure or some of those specific names like the pfizers or the mercks on the megacap names. >> i'm in sell ji, a biopharma play, up about 16% since that move that landon just talked about. i'm sticking with that one i'm in bristol and it's not moving it's a little better than the s&p over the same time frame

as a result, regeneron shares rose to 495.33 while novartis was up a fraction to 81.60. >>> red hat raised its earnings and sales outlook for the year. after reporting earnings and e ahead of estimates. the company cited robust global demand and increased commitment from its largest mecustomers. shares took off in after hour, but ended the regular session down marginally. >>> for the first time now, uber is is going to allow drivers to collect tips through the company's smart phone app. the decision is part of a broader effopr the company's relationship with its drivers. drivers have long argued that tips would help compensate for decreased wages. the feature will be available by the end of july. >> a lot of grumbling around here when that came through. the the operator is calling for voluntary electricity conservative vegas in the afternoon and evening. this is first su. officials say consumers shouldn't use manl appliances during those hours and turn off unnecessary lights. in fien iphoenix, american airl canceled some shorter flights. >>> coming up u, is the tax code too long and too ol

regeneron is one of the , it's fiamma sickles and biotech, -- pharmaceuticals prescriptiveand growths of deceleration. that is according to reports that perceptions fell 2% in the week of june 16 compared to the prior week. 3%, butares down regeneron, like much of biotech, has had a strong week. if you look at either the 60 i -- x the ietf or the nasdaq index, both have had strong weeks. you are seeing in today's esch and that they are diverging. both of them are up by the bet on the week. -- xei going back up again, you've over the health care bill, we were seeing some strength in this group. that is also evident by the fund .lows into the xc i this shows the daily fund flow -- i should say weekly fund flow for the xc i, and you can see there is a decent of take in the last week as people were buying into this particular etf. julia? julia: now president donald that hes an admission never taped conversation with now former fbi director james comey. this could expose them to new legal issues and might weaken his credibility in the eyes of investigators probing ties between the preside

she alluded to dupixant from regeneron and you have benchly who's been the ceo at regeneron for a number-founder and this is for atopic dermatitis itching. it affects 300,000 individuals in the united states the scripts have been jumping off the page and it was just approved in march. so what we think is that that's an opportunity set but you know what? it's really a drug and a drug cabin cabinet. it's not only a drug for atopic dermatitis the argument is it may have utility in asthma and a number of other allergies because of the exact focus that's been founded by regeneron of how the drug works if you could stop that signaling down that pathway maybe you can reduce -- and the argument might be, there was some estimates that are in excess of $10 billion for this opportunity a drug in a drug cabinet so it's just a consideration i think that's where investors are going to want to point >> what about the other big guise? what about pfizer? >> pfizer is a little bit treading water doesn't have a number of new products that are large enough to drive the overall revenue and earnings per share

we're taking regeneron's pd 1 inhibitor. >> very important drug. >> very important drug and combiningwith our 54-1 one of my favorite cancers for inovio, we're swinging for the fences. i know you're a baseball fan. >> if the phillies were better i would be even more a fan. you've been at this a long time. you're playing the long game. you admit it's a long game before you get to fruition for everything. >> normally yes. in immunology and cancer there are break through things and fast tracking depends on the data. i'm convinced on the data we have thus 4. 54-1 and pd 1 inhibitor will bring about very good data. >> i don't want to get folks too excited but you have an exciting company. the president of the fatherlies company next door to where i'm from, after the break. think again. this is the new new york. we are building new airports all across the state. new roads and bridges. new mass transit. new business friendly environment. new lower taxes. and new university partnerships to grow the businesses of tomorrow today. learn more at esd.ny.gov ray's always been different. last year,

meanwhile, just get this one, in the last two months, regeneron has gone from 370 to 522 i would argue that information wouldn't have done much at all to boost the stock without this new, more positive backdrop that comes from a slower economy. it's not just biotech. j and j went from 122 to 135 over that same time frame. i think the main driver here is the rotation into the stocks of companies that do well when the economy is weak, or when there's deflation. and boy, is there deflation. it doesn't hurt that j and j is the ultimate stock to buy. workday, service now, and red app have exceeded all expectations, producing winner after winner, including oracle, which crushed the numbers this very evening cloud adoptions is going main stream the growth has been from many different regions. we thought cloud was finished years ago when mark used to come on and say -- hey, let me tell you something, it's phil murray's second inning almost any semi conductor enter fete of things, iot, whatever you want to call it, company connected with the cloud has been a winner. any company that benefits fr

regeneron has been gaining steam in particular. stocks fell initially today after novartis said a potential blockbuster it's developing to treat vision loss could mean fewer injections for patients . that study was not as strong as it first appeared. it could be delayed. lnylam --ark this biotech etf breaking to the upside. it had lacked the nasdaq for much of this year. it is now play catch-up in a big way. staying with market some of the dollar is rising and treasuries are falling. today, david gura spoke to steve mnuchin and talked to him about the strong dollar and long bonds. first, he asked him about comments suggesting his investment decisions are based on national security. david asked if he be in favor of an economic reinvestment in the u.s. steve: they are completely on national security. --avor national security there's other things we can do to make sure that we are economically competitive. the u.s. is one of the free is trading markets in the world. one of the priest investment markets in the world. we welcome foreign

sanofi and regeneron said their cholesterol drug had both diabetes and high cholesterol.s presented at the annual meeting of the american diabetes association and teeva pharmaceuticals looks to refresh the board following a series of acquisitions and delayed launches on its drug for multiple sclerosis is facing some generic competition >> when we come back we'll be talking to apple cofounder steve wozniak about the state of the technology industry and why he says tesla will be behind the next moon shot not apple coming up at 8:30. tomorrow on "squawk box" the conversation you won't want to miss billionaire investor ron baron will be our guest at 7:00 a.m. eastern time. you are watching "squawk box" right here on cnbc and the wolf huffed and puffed... like you do sometimes, grandpa? well, when you have copd, it can be hard to breathe. it can be hard to get air out, which can make it hard to get air in. so i talked to my doctor. she said... symbicort could help you breathe better, starting within 5 minutes. symbicort doesn't replace a rescue inhaler for sudden symptoms. sym